Stereotactic body radiation therapy in lymph nodal oligometastatic disease
Phase 2
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2023/02/049773
- Lead Sponsor
- PGIMER CHANDIGARH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Lymph node oligometastatic disease in the neck, mediastinum, retroperitoneum, or pelvis
2) All primary tumors of colorectal, gastric, esophagus, lung, breast, gynaecological cancers or any other site
3) KPS = 70
4) Age > 18 years
Exclusion Criteria
More than 5 metastases
2) KPS = 60
3) Pre-existing collagen vascular disease
4) Age < 18 years
5) Pregnant and Lactating women
6) Disseminated disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) To assess Overall survival <br/ ><br>2) To assess Progression Free Survival <br/ ><br>Timepoint: 6 months, 1 year <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1)To evaluate adverse events according CTCAE <br/ ><br>2)To evaluate chemotherapy-free survival <br/ ><br>3)Quality of life with EORTC QLC C30 <br/ ><br>Timepoint: At 3 months, 6 months, 12 months